A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs BLI 1100 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Braintree Laboratories
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 18 May 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2015 New trial record